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INTRODUCTION
Ever since the crucial description by Jonathan 
Hutchinson in 1877 and Caesar Boeck in 1899, 
sarcoidosis has fascinated the medical fraternity 
with its protean manifestations and unknown 
aetiology. The „Statement on Sarcoidosis”, 
issued jointly by the American Thoracic Society 
(ATS), the European Respiratory Society (ERS) 
and the World Association of Sarcoidosis and 
Other Granulomatous Disorders (WASOG), 
has a descriptive definition that spans four par­
agraphs. A definition as lengthy as this reflects 
the stark reality that till today the cause of this 
disease still eludes us [1, 2].
Sarcoidosis is the disease that causes 
immense curiosity and anxiety, both among 
sufferers and their care providers. In more than 
90% of patients, lungs are involved, therefore 
chest physicians are those who see the patients 
first and guide them through diagnostic pro­
cedures [3]. However, sarcoidosis is a complex 
multiorgan disease with multiple non­specific 
symptoms. Sometimes these symptoms go 
beyond the usual experience of chest physi­
cians. Fatigue is an integral part of the clinical 
picture of sarcoidosis [4].
DEFFINITION OF FATIGUE
It is quite difficult to find a proper definition 
on fatigue in general, or fatigue in sarcoidosis. 
In the last five years approximately 30 articles 
dealing with fatigue in sarcoidosis patients were 
published, but no one cited a proper definition 
[5­8]. „Fatigue is a common symptom and the 
symptom that has been with us forever...”, as 
started by Dr. Om Sharma [9] his editorial 
article on fatigue in sarcoidosis written for 
the European Respiratory Journal in 1999. As 
Samuel Butler stated years ago, life is a long 
process of getting tired [9].
What is the definition of fatigue? There are 
many synonyms in a dictionary like: exhaus­
tion, tiredness, weariness, low energy, weak­
ness. But not a single one satisfies the proper 
meaning of fatigue in the terms of this topic. 
Fatigue (also called exhaustion, languidness, 
languor, lassitude, or listlessness) is a weariness 
caused by exertion. It describes a range of afflic­
tions, varying from a general state of lethargy 
to a specific work­induced burning sensation 
of muscles. It can be both physical and mental. 
Physical fatigue is inability to continue func­
tioning at the level of normal abilities. Mental 
fatigue, on the other hand, rather manifests in 
somnolence [10]. Fatigue may also be defined 
as a reduction in the maximal force­generating 
capacity of a muscle [11, 12].
The word fatigue originates from the experi­
ence in healthy individuals, but interview based 
studies have revealed that even though patients 
label their sensation as fatigue, they often find 
it qualitatively very different from the fatigue 
they experienced before they became sick [13]. 
These findings indicate that the story of fatigue 
needs a continual multidimensional approach 
with the analyses involving its physical, cogni­
tive, emotional and functional parts [6].
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Before proceeding with the topic, it is very important 
to emphasize the difference of the two terms and two dif­
ferent, although equally bothersome, unpleasant condi­
tions: chronic fatigue syndrome (CFS) and chronic fatigue. 
Fatigue is a common symptom in many illnesses, but CFS 
is a multi­systemic disease and is relatively rare by com­
parison. CFS is one of several names given to a poorly 
understood, variably debilitating disorder of uncertain 
cause/causes. Most diagnostic criteria require that symp­
toms must be present for at least six months and all state 
the symptoms must not be caused by other medical con­
ditions. It is extremely important to distinguish the two 
topics [14, 15].
FATIGUE IN SARCOIDOSIS
Fatigue is a common symptom in a large number of med­
ical conditions such as rheumatoid arthritis, malignant 
diseases and infectious diseases. However, several studies 
in the past decades have shown that fatigue is a promi­
nent symptom of sarcoidosis [16­20]. The occurrence of 
fatigue in sarcoidosis is well known, but exact incidence has 
not been established and varies from 30­70% of patients 
depending on age, sex, race and organ involvement by the 
granulomatous process [21, 22].
There are many different approaches to the cause of 
fatigue in sarcoidosis. In Table 1 the most important factors 
related to fatigue in sarcoidosis are presented [8, 23­27].
There are four types of fatigue that can be recognized in 
sarcoidosis (Table 2) [9, 28]. For clinical purposes the dura­
tion of fatigue can be divided into less than 3 months, 3­6 
months and longer than 6 months. In patients with fatigue 
persisting for more than 3 months the evaluation of other 
organs and systems should be performed. In patients with 
fatigue lasting beyond 6 months anxiety disorders, stress 
and depression should be considered [9].
Sarcoidosis predominantly affects the patients of young 
age, thus it may be more difficult to cope with this sympto­
matic multi­organ disease of unknown origin and unpre­
dictable course than at older age. A chronic disease like 
sarcoidosis at young age may result in social problems, 
especially when the patient looks healthy, but suffers from 
serious loss of working capacity. Unfortunately, there is no 
objective method for establishing the degree of disabling 
fatigue and the long lasting loss of working ability.
DETECTION OF SARCOIDOSIS ASSOCIATED FATIGUE
How to detect fatigue in sarcoidosis?
There is no objective parameter either for asserting fatigue 
in general or in sarcoidosis. Generally, fatigue is detected 
by means of questionnaires.
The authors of a bibliographic study of fatigue meas­
urements scales found in the last thirty years (1975–2004) 
searching Medline and Psych/INFO a total number of 2285 
papers reporting the measures of fatigue in somatic and 
psychiatric diseases that were published between 1975 and 
2004. An exponential increase in the number of fatigue 
studies was observed, and it was noticed that 80% of the 
studies were published during the last 10 years of that 
period. They defined no less than 252 different methods 
to assess fatigue, of which 150 were used only once. In 
670 fatigue studies, fatigue was measured by one of 157 
multi­symptom scales as one of several domains, like the 
generic questionnaire Short Form 36­item Health Survey 
(SF­36) or Cancer Specific EORTC QLQ­C30 [29, 30]. 
The majority of fatigue studies used fatigue scales with a 
multidimensional approach typically divided into a cog­
nitive and mental part, where the latter could be divided 
into the cognitive and emotional part [5]. According to 
Dittner et al. [6], different manifestations and a wide range 
of mechanisms possibly causing fatigue makes it unlikely 
that any fatigue scale will ever be appropriate for measuring 
fatigue in all disease groups. Nevertheless, since fatigue is 
an unspecific symptom there is no need for developing dis­
ease specific fatigue scales for each individual disease [5].
Fatigue has a major impact on the quality of life 
(QOL) in sarcoidosis. Establishing the extent of fatigue 
will provide important insight regarding patients' QOL. 
Table 1. Possible causes of fatigue in sarcoidosis [7, 23­27]
Basic causes
General inflammation and metabolic 
dysfunction
Myopathy (caused either by granulomatous 
inflammation or therapy, for example steroid 
myopathy)
Sleeping disorders (obstructive sleep apnea 
syndrome, restless legs syndrome)
Pain (specific types of pain: chest pain, 
arthralgia, headache, etc.)
Lack of exercise can be a cause of fatigue in 
sarcoidosis
Psychological factors (considerable number of 
sarcoidosis patients are diagnosed with 
depression the major symptom of which is 
fatigue)
Causes  
related to 
psychological 
factors
Perceived stress related to fatigue
Development of fatigue and depressive 
symptoms nay be attributed CNS involvement
Small fibre neuropathy (SFN) is common among 
sarcoidosis patients. Sarcoidosis patients with 
SFN are reported with higher fatigue scores 
(FAS) than those without SFN.
Table 2. Clinical manifestations of sarcoidosis associated fatigue [9, 28]
Early morning 
fatigue
Patients wake­up unrested because of joint 
stiffness or muscle pain. This type of fatigue is 
also seen in patients with autoimmune diseases.
Intermittent 
fatigue
Patients wake­up feeling normal but after few 
hours of activity feel tired and exhausted. 
Throughout the day they need periods of rest.
Afternoon 
fatigue
Patient wake­up in the morning feeling 
energetic but become tired in the early 
afternoon. These patients evaluate their fatigue 
as a „flue­like syndrome”. They go to bed early 
and stay in bed until next morning.
Post­
sarcoidosis 
chronic fatigue 
syndrome
Presence of fatigue in persons with history of 
sarcoidosis, (normal chest radiograph and 
markers of disease activity). Main symptoms: 
widespread myalgia, unbearable fatigue and 
depression. Physical signs during examination 
are absent. Lack of any objective evidence 
confuses both the patients and physicians.106
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Table 3. The variety of quality of life (QOL) and health status (HS) que­
stionnaires used in patients with different interstitial lung diseases and 
sarcoidosis [31]
CRQ* Chronic Respiratory Questionnaire  
(HS questionnaire)
SF­36* Short Form 36­ item Health Survey  
(HS questionnaire)
SGRQ St George’s Respiratory Questionnaire  
(HS questionnaire)
SHQ
Sarcoidosis Health Questionnaire  
(HS questionnaire and the only disease specific 
questionnaire for patients with sarcoidosis)
SIP* Sickness Impact Profile (HS questionnaire)
WHOQOL­100 100­item World Health Organization Quality of 
Life Instrument (QOL questionnaire)
* validated in interstitial lung disease patients including patients with sarcoi­
dosis [9]
It is however, important to emphasize two different but 
equally important items: QOL and health status (HS). QOL 
is defined as the individual’s overall satisfaction with life 
and functional status. However, HS refers to the impact 
of disease on patients' physical, psychological and social 
functioning. QOL refers to patients' perception or evalu­
ation of their functioning. Both QOL and HS refer to as 
a health­related quality of life (HRQOL) is increasingly 
recognized as important measures of disease impact and 
therapeutic outcome [31]. Both concepts consist of physi­
cal, psychological and social domain.
Using the right type of questionnaire for achieving the 
desired aim is of the highest importance, since QOL and 
HS measures may even yield opposing results. The choice 
of QOL or HS measure depends on the aim. In general, if 
information is required about what patients can or cannot 
do (physical functioning sphere) the HS measure should be 
used. However if the interest is in how patients’ experience 
regarding different aspects of their lives, the QOL measure 
is indicated [31]. The variety of QOL and HS question­
naires has been used in patients with different interstitial 
lung diseases and sarcoidosis (Table 3) [31].
quality of life and health status questionnaires used 
in measuring fatigue associated with sarcoidosis
World Health Organization Quality of Life assessment 
instrument (WHOQOL-100)
Until now the WHOQOL­100 questionnaire is the only 
QOL general instrument that has been used in sarcoidosis. 
The WHOQOL­100 is a cross culturally developed generic 
multidimensional QOL measure that has been simultane­
ously developed in 15 centres worldwide (France, Russia, 
USA, Japan, and Thailand) [32]. The WHOQOL­group 
has defined QOL as an individual perception of his/her 
position in life in the context of culture and value systems 
in which he/she lives and in relation to their goals, expecta­
tions, standards and concerns.
The WHOQOL­100 consists of 100 items assessing 24 
facets of QOL within six domains: physical health, psycho­
logical health, level of independence, social relationships, 
environment and spirituality, religion, personal beliefs and 
a general evaluative facet – overall QOL and general health. 
Each facet is represented by four items. The response scale 
is a five­point Likert scale, ranging from 1 (never) to 5 
(always), with higher scores showing a better QOL for the 
facet or domain [31, 32].
Fatigue Assessment Scale (FAS)
The FAS is a fatigue questionnaire consisting of 10 items; 
five questions reflecting physical fatigue and five questions 
for mental fatigue. The response scale is a 5­point scale 
ranging from 1 (never) to 5 (always). Scores on the FAS 
can range from 10­50; cut off 22 [33].
Daily Activity List (DAL)
The degree of limitation in activities of daily living was 
evaluated with the List of Daily Activities (DAL), a scale 
that was originally designed by Stewart et al. The scale 
has been used in several studies in patients with chronic 
pulmonary diseases and sarcoidosis [34, 35].
The DAL contains 11 items that are related to the usual 
activities which persons in good health can perform with­
out particular effort. The number of positive responses 
comprises the DAL score and indicates the degree of 
impairment.
Mental-psychological functioning and fatigue
The association between psychological factors and dis­
ease gained its scientific support in the beginning of the 
20th century, and was initiated by researches working in a 
wide variety of fields. Early research suggesting that physi­
cal illness has a psychosomatic component was strongly 
dominated by psychoanalytical theory, an extension of the 
Freudian idea that symptoms are a symbolic expression of 
unconscious conflicts and repressed desires.
The relationship between fatigue and emotional stabil­
ity is another important issue for the clarification of the 
concept of fatigue in sarcoidosis [34]. Although Klonoff 
and Kleinhenz [20] suggested that sarcoidosis patients 
as a group did not meet criteria for clinical depression, 
awareness of bodily sensations, however, was found to be 
associated with more depressive symptoms and escaping 
activities when alone [37­39]. Quite a few psychological 
functioning scales have been used in the assessment of 
emotional and mental functioning in interstitial lung dis­
eases including sarcoidosis [39­43]. Magnusson et al. [44] 
found that emotional stability was the main predictors of 
fatigue. According to these authors, neurotic individuals 
may be more fatigue prone, given their general tendency 
to stress symptoms [44].
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How to Detect Depression Associated with Fatigue?
Quite a few scales measuring depression have been used 
in patients with different pulmonary diseases but mostly 
chronic obstructive pulmonary disease (COPD).
Centre for Epidemiologic Studies Depression Scale 
(CES-D)
The scale originated from the Centre for Epidemiologic 
Studies in Oxford, and has been successfully used in inves­
tigations on the QOL in patients with interstitial lung 
diseases, among them a group of sarcoidosis patients as 
well [41]. The full CES­D is a 20­item self­report scale 
designed to measure the presence and the degree of depres­
sion symptomatology in a broad­based survey research 
populations. The rating scale ranges from 1 (seldom or 
never) to 4 (almost always). A score of 16 or higher indi­
cates depression.
DySPNEA AS THE POSSIBLE CAUSE OF FATIGUE  
IN SARCOIDOSIS
The most common symptom of patients with cardio­res­
piratory diseases is dyspnea. Dyspnea has been defined 
as a term used to characterize a subjective experience of 
breathing discomfort that consists of qualitatively dis­
tinct sensations that vary in intensity. The experience 
derives from interactions among multiple physiological, 
psychological, social and environmental factors, and may 
induce secondary physiological and behavioural responses. 
Nevertheless, there is no clear relationship between the 
qualitative descriptors of dyspnea and the quantitative 
intensity among the patient groups; different diseases may 
be distinguished by quality, but not intensity of the sensa­
tion. However, dyspnea is a common symptom in patients 
with sarcoidosis [45, 46].
In our own experience dyspnea, as a symptom possi­
bly related to HRQOL and fatigue, was determined by the 
Baseline Dyspnea Index (BDI) and the Modified Medical 
Research Council (MRC) [34].
The BDI divides dyspnea into three components: the 
degree of the functional impairment, the level of the activ­
ity, and the level of effort required to develop dyspnea. Each 
component is graded on a five­point rating scale from 0 
(extreme impairment) to 4 (without impairment); therefore 
the total BDI score can range from 0 to 12 [34].
The MRC classifies subjects into one of five categories 
according to their degree of dyspnea when performing 
certain activities. Scores range from 0 to 4; higher scores 
indicate more severe dyspnea [34].
PATIENT HEALTH STATUS AND FATIGUE
Two standardized questionnaires have been used among 
Serbian population of sarcoidosis patients to measure 
health status: a generic measure, the fifteen­dimensional 
(15D) measure instrument of HRQOL and a respiratory­
specific measure, the St George’s Respiratory Questionnaire 
(SGRQ) [34].
The fifteen­dimensional (15D) is a multi­attributive 
instrument for the measurement of HRQOL [34]. It was 
originally developed and validated on a large Finnish popu­
lation. The 15D was used in different diseases in many 
different countries. The Serbian version of 15D was previ­
ously used in patients with asthma where it demonstrated 
good psychometric measurement properties [34]. The 
15D includes 15 different and mutually exclusive health 
dimensions: mobility, vision, hearing, breathing, sleeping, 
eating, speech, elimination, usual activities, mental func­
tion, discomfort and symptoms, depression, distress, vital­
ity, and sexual activity, each represented by one item. The 
total questionnaire score ranges between 0 and 1, where 1 
signifies the highest level of health status.
The Saint George’s Respiratory Questionnaire (SGRQ) 
is an instrument that was originally designed to measure 
the health status of COPD patients. Its validity, reliability, 
and responsiveness were also shown in other pulmonary 
diseases. The questionnaire consists of 50 items with 76 
responses, and encompasses three domains of health status: 
[1] symptoms, focusing on distress because of respiratory 
symptoms, [2] activities, measuring decreased mobility or 
physical activity and [3] impacts, measuring the psychoso­
cial influence of disease on the everyday life and patients’ 
well being. The scores of these domains, as well as the 
total score, are scaled from 0 to 100, where higher scores 
represent a poorer quality of life [47].
In a study of Gvozdenovic et al. [34], the severity of 
fatigue was measured using the health status measurement 
in two groups of sarcoidosis patients, with and without 
extra pulmonary disease. The results showed that those 
with pulmonary plus extra pulmonary sarcoidosis had 
statistically and clinically worse health status in terms 
of SGRQ scores than those with isolated pulmonary sar­
coidosis. This is an interesting finding since the SGRQ is a 
respiratory­specific questionnaire. A possible explanation 
for this is that several items of the questionnaire relate to 
physical activities and the impact of disease on the patients’ 
level of functioning, as well as fatigue. It is possible that 
extrapulmonary manifestations of sarcoidosis had a nega­
tive impact on these items. The same was confirmed in 
studies of Cox et al. [8].
In the same study, the 15D, a generic measure of health 
status did not show a statistically significant difference 
between the isolated pulmonary and pulmonary plus 
extrapulmonary groups, although the mean score reflected 
a poorer health status in the latter group. In the same study, 
Gvozdenovic et al. [34] showed that the dyspnea level was 
worse in patients with pulmonary and extra pulmonary 
sarcoidosis. This was demonstrated using the BDI measure 
but not the MRC.
The MRC addresses only the level of activities that leads 
to dyspnea without consideration of the associated effort 
necessary for the performance of particular activity, which 
is essential for patients with fatigue [34]. However, the BDI 
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assesses the degree of the functional impairment, which 
represents an important outcome of dyspnea. Since the 
patient’s perception of dyspnea depends on the physical 
activities and the required effort, patients with extra pul­
monary involvement may feel breathlessness because of 
their functional limitations.
Although our patients feeling fatigued had significant 
dyspnea, they perceived limitations in their physical activi­
ties, and had a poor health status, but with normal pulmo­
nary function. This confirms reports by previous studies 
demonstrating that pulmonary function testing cannot 
function as a substitute for all these other parameters and 
cannot be used to assess the overall health of sarcoidosis 
patients [34].
THERAPy OF SARCOIDOSIS ASSOCIATED FATIGUE
There are studies suggesting that patients using prednisone 
exhibited higher fatigue scores than patients who did not 
use prednisolone [33]. Several case reports of sarcoidosis 
patients treated with antitumour necrosis factor TNF­α 
showed a dramatic reduction in fatigue. This kind of drug 
however, cannot be administered to patients suffering 
exclusively from fatigue without other evidence of disease 
activity [31, 33].
There is no effective treatment for fatigue in sarcoido­
sis. There have been several clinical trials of d MPH dex­
methylphenidate hydrochloride in treating patients with 
sarcoidosis associated fatigue [48]. Methylphenidate has 
been already used in the treatment of fatigue in patients 
with cancer, HIV infection and CFS. The drug has also 
been reported to be effective for patients with confirmed 
depression, which is an essential part of clinical features 
in patients with fatigue [48].
CONCLUSION
Еven though fatigue is a well­known symptom of sar­
coidosis, the problem of fatigue in this multisystem disease 
has not been taken seriously enough in clinical practice. 
Objective test results (chest X­ray, laboratory findings and 
inflammatory parameters) are not always in correlation 
with the objective well­being from the patient’s perspec­
tive. There is no sufficient therapy available up­to­now. It is 
very important to instruct clinicians and other physicians 
involved in the follow­up of patients with sarcoidosis that 
the lack of objective parameters is not always a guarantee 
of the person’s healthy condition.
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КРАТАК САДРжАЈ
За мор је зна ча јан симп том ко ји пра ти ве ли ки број ме ди цин­
ских ста  ња и ма  лиг  них и ин  фек  тив  них обо  ље  ња. Он је та­
ко ђе  ис так ну ти  симп том  сар ко и до зе.  Иако  је  по ја ва  за мо­
ра у сар ко и до зи ве о ма до бро по зна та, ње го ва уче ста лост у 
овој  бо ле сти  још  ни је  тач но  утвр ђе на.  Прет по ста вља  се  да 
је  из ме ђу  30%  и  70%,  у  за ви сно сти  од  ста ро сти  бо ле сни ка, 
по ла  и  за хва ће но сти  по је ди них  ор га на  про це сом  гра ну ло­
ма то зе. Тач на де фи ни ци ја за мо ра та ко ђе се ве о ма раз ли ку­
је.  По сто је  фи зич ка  и  мен тал на  ком по нен та  за мо ра.  Бо ле­
сни ци  опи су ју  свој  осе ћај  за мо ра  ква ли та тив но  раз ли чи­
то у од но су на за мор ко ји су има ли пре не го што су по ста ли 
бо ле сни.  За мор  има  ве ли ки  ути цај  на  ква ли тет  жи во та  осо­
ба  обо ле лих  од  сар ко и до зе.  Од ре ђи ва ње  сте пе на  из ра же­
но сти  за мо ра  у  сар ко и до зи  пру жа  зна ча јан  увид  у  про це ну 
по гор ша ња  ква ли те та  жи во та  бо ле сни ка.  На жа лост,  не  по­
сто ји објек ти ван па ра ме тар за про це ну за мо ра у сар ко и до­
зи.  Обич но  се  сте пен  те жи не  за мо ра  од ре ђу је  здрав стве­
ним  упит ни ци ма.  За сад  не  по сто ји  ефи ка сно  ле че ње  осо ба 
са  сар ко и до зом  од  за мо ра.
Кључ не  ре чи:  сар ко и до за;  за мор;  от кри ва ње
Замор у саркоидози: откривање и лечење
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